GILD vs QGEN
Gilead Sciences, Inc. and Qiagen N.v., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | GILD | QGEN |
|---|---|---|
| Revenue | $29.4B | $2.1B |
| Net income | $8.5B | $424.9M |
| Gross margin | 78.8% | 62.2% |
| Net margin | 28.9% | 20.3% |
| Return on equity | 40.5% | 11.6% |
| Diluted EPS | $6.78 | $1.94 |
| Dividend / share | $3.16 | $0.25 |
| Payout ratio | 47.0% | 12.8% |
| Free cash flow | $9.5B | $453.3M |
| Equity | $22.7B | $3.8B |
| Net debt / equity | 0.77× | 0.22× |
| Current ratio | 1.55× | 3.90× |
| Revenue CAGR 5y | 3.6% | 2.2% |
| Profit CAGR 5y | 133.3% | 3.4% |
GILD bills 14.1× the revenue of QGEN, and keeps more of each dollar of revenue as profit (28.9% against 20.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | GILD | QGEN |
|---|---|---|
| FY2025 | $29.4B | $2.1B |
| FY2024 | $28.8B | $2.0B |
| FY2023 | $27.1B | $2.0B |
| FY2022 | $27.3B | $2.1B |
| FY2021 | $27.3B | $2.3B |
| FY2020 | $24.7B | $1.9B |
| FY2019 | $22.4B | $1.5B |
| FY2018 | $22.1B | $1.5B |
| FY2017 | $26.1B | $1.4B |
| FY2016 | $30.4B | $1.3B |
Bottom line
| Fiscal year | GILD | QGEN |
|---|---|---|
| FY2025 | $8.5B | $424.9M |
| FY2024 | $480.0M | $83.6M |
| FY2023 | $5.7B | $341.3M |
| FY2022 | $4.6B | $423.2M |
| FY2021 | $6.2B | $512.6M |
| FY2020 | $123.0M | $359.2M |
| FY2019 | $5.4B | $-41.5M |
| FY2018 | $5.5B | $190.4M |
| FY2017 | $4.6B | $40.4M |
| FY2016 | $13.5B | $80.4M |
18 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$27,353,001,000 | GILD |
| FY2024 | +$26,775,786,000 | GILD |
| FY2023 | +$25,150,689,000 | GILD |
| FY2022 | +$25,139,482,000 | GILD |
| FY2021 | +$25,053,343,000 | GILD |
| FY2020 | +$22,818,654,000 | GILD |
| FY2019 | +$20,922,576,000 | GILD |
| FY2018 | +$20,625,152,000 | GILD |
| FY2017 | +$24,689,464,000 | GILD |
| FY2016 | +$29,052,009,000 | GILD |
| FY2015 | +$31,358,014,000 | GILD |
| FY2014 | +$23,545,223,000 | GILD |
| FY2013 | +$9,900,016,000 | GILD |
| FY2012 | +$8,447,544,000 | GILD |
| FY2011 | +$7,215,638,000 | GILD |
| FY2010 | +$6,861,989,000 | GILD |
| FY2009 | +$6,001,558,000 | GILD |
| FY2008 | +$4,442,775,000 | GILD |
GILD has reported the higher revenue in every one of these 18 fiscal years. The gap has widened since the earliest year compared.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
18 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +8.6 pp | GILD |
| FY2024 | −2.6 pp | QGEN |
| FY2023 | +3.3 pp | GILD |
| FY2022 | −3.0 pp | QGEN |
| FY2021 | −0.1 pp | QGEN |
| FY2020 | −18.8 pp | QGEN |
| FY2019 | +26.6 pp | GILD |
| FY2018 | +12.0 pp | GILD |
| FY2017 | +14.9 pp | GILD |
| FY2016 | +38.4 pp | GILD |
| FY2015 | +45.3 pp | GILD |
| FY2014 | +39.8 pp | GILD |
| FY2013 | +22.0 pp | GILD |
| FY2012 | +16.2 pp | GILD |
| FY2011 | +25.1 pp | GILD |
| FY2010 | +23.1 pp | GILD |
| FY2009 | +23.8 pp | GILD |
| FY2008 | +26.9 pp | GILD |
The higher net margin has changed hands between GILD and QGEN over this period.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
GILD's net margin has been more volatile than QGEN's over the 18 comparable fiscal years — 14.0 percentage points of standard deviation against 6.7.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between GILD and QGEN over these 18 fiscal years — GILD led in 14 and QGEN in 4.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
GILD's return on equity has been more volatile than QGEN's over the 18 comparable fiscal years — 26.6 percentage points of standard deviation against 4.7.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between GILD and QGEN over these 18 fiscal years — GILD led in 17 and QGEN in 1.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.